Board of Directors
A Dedicated Team with Depth and Experience in Life Science Leadership
Chief Executive Officer
Joe Victor serves on the Board of Directors at Rarecyte and has been a Venture Partner with 5AM Ventures since 2016. Prior to his joining 5AM Ventures, Mr. Victor served as CEO of Startide Sciences, a 5AM Ventures portfolio company chartered to identify and develop innovative technologies in the Life Sciences research tools markets. Prior to Startide, Mr. Victor served as CEO of DVS Sciences (acquired by Fluidigm Inc.), and Applied Precision Inc (acquired by GE Healthcare). He currently serves as Executive Chairman on the boards of Biodesy and Purigen Biosystems as well as on the Boards of RareCyte, Precision Nanosystems, and Glencoe Software. Mr. Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation. Mr. Victor has also held various executive management and technical positions in the high technology, aviation, and energy markets. Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington.
Chief Technology Officer
Ron brings a wealth of corporate leadership and technical experience to RareCyte. Prior to founding RareCyte, he was a founder and CEO at Applied Precision, Inc. (API). API initially specialized in semi-conductors. The company eventually spun off this division and began creating innovative imaging solutions for life sciences. Ron was instrumental in launching the popular DeltaVision line of microscopes, including the DeltaVision Elite and DeltaVision OMX, one of the first super-resolution imaging systems on the market. The company was sold to GE Life Sciences in 2011. His professional experience spans decades and he holds several patents.
Robert G. Shepler
Telegraph Hill Partners
Bob has been a corporate transactions specialist and investor since 1978, with a focus on strategic M&A transactions. Bob and Matt Mackowski partnered together in 1991 to form THP’s predecessor focused on investing in private healthcare companies. During his career, he has served on numerous company boards and completed over 200 M&A and financing transactions. Bob has represented THP on the boards of Kinetikos Medical (acquired by Integra), AcroMetrix (acquired by Life Technologies), Agena Bioscience, Akoya Biosciences, Aurora Discovery (acquired by NEXUS Biosystems), Applied Precision (acquired by GE), Dynex, LDR Spine (NASDAQ:LDRH), Estech (acquired by AtriCure), RareCyte, Sage Labs (acquired by Horizon Discovery) and Vidacare (acquired by Teleflex). He is currently an observer on the boards of Magstim and Precision NanoSystems. Prior to joining with Mr. Mackowski, Bob worked with Merrill Lynch & Co. as an officer in their San Francisco corporate finance office, where he managed financings and acquisitions for Fortune 500 and selected high growth companies. Bob received a BA from Duke University and an MBA from New York University.
Frank Witney, Ph.D.
Frank, who joined Ampersand as an Operating Partner in 2016, serves as Chairman of Gyros Protein Technologies. Frank most recently served as CEO of Affymetrix, a leading provider of genomics and cell biology products that was sold in 2016 for $1.3 billion. Previously, Frank was CEO of Dionex, a leading provider of analytical instrumentation that was sold in 2011 for $2.1 billion. He also held senior executive positions at Perkin Elmer, Packard Bioscience and Bio-Rad Laboratories. Frank holds a Ph.D. in molecular and cellular biology from Indiana University.
Brian Daniels, MD
Brian Daniels, M.D. joined 5AM Ventures as a Venture Partner in 2014 and transitioned to Partner in 2018. Dr. Daniels previously spent over two decades in clinical drug development, including leading the Development and Medical Affairs at Bristol-Myers Squibb for the last ten years. He directed the development of numerous innovative medicines that have contributed to the improvement for patients across a range of serious diseases. These include: ORENCIA and NULOJIX in immunology/transplant, REYATAZ, DAKLINZA and BARACLUDE in virology, ONGLYZA, FARXIGA and MYALEPT in metabolics, ELIQUIS in CV and YERVOY, OPDIVO, SPRYCEL and IXEMPRA in oncology. Dr. Daniels is currently a Director at these 5AM companies: Spyryx Bioscience, Nohla Therapeutics, Rarecyte, and Ideaya Biosciences (independent). He leads the Clinical Advisory Board for Aprea Therapeutics and is the acting Chief Medical Officer for Expansion Therapeutics. He also served on the Scientific Advisory Board of Novira. Dr. Daniels received B.S. and M.S. degrees from MIT and his M.D. from Washington University in St. Louis. He trained in internal medicine at New York Hospital and Rheumatology/Immunology at UCSF. Dr. Daniels is based in the San Francisco, CA office.